Research Article
BibTex RIS Cite

The treatment of metastatic prostate carcinoma with BNCT in the ITU TRIGA MARKII reactor on rat model

Year 2016, Volume: 3 Issue: 12, 350 - 358, 29.12.2016

Zafer Akan Hulya Ozdemir Mehmet Bilgehan Yuksel Gokhan Oto Hatice Sinav Uslu Mehmet Turkmen

https://doi.org/10.17546/msd.270421

Abstract





Objective:  The delivery of curative radiotherapy is commonly has the potential of
serious side effects. These side effects still remain dose-limiting factor
for external beam radiotherapy and as also curative treatment of prostate
cancer (PCa). New treatment alternatives, such as BNCT, are investigated to
eliminate these limitations and to improve the therapeutic efficiency of
radiation on tumour cells including prostate cancer. In this study, we
investigated the efficiency of BNCT application by using our novel 10B
carrier that was called as 10B-DG on PCa using an in vivo mouse xenograft
model.


Material and
Methods: PCa
bearing Copenhagen rats (CRs) were used in this experimental animal study. A
total of 12 CRs at the age of 2 months were used in this experimental animal
study. MAT-LyLu PCa cells were injected subcutaneously into the peritoneal
cavity of rats to create PCa model. The samples were divided into 4 groups:
As, control, neutron irradiated, 10B-DG and 10B-DG + neutron irradiated
group. 10BDG was administrated to tumour bearing rats and rats were exposed
to 8.074 gy/hr thermal and epithermal. Tumour sizes were regularly measured
by microtome and PET scan along 20 days.


Results: The results have shown that the
tumor growth were regressed just in 10B-DG + neutron irradiated group. In
addition that, PET-CT scan results revealed that 18FDG uptake was stopped in
the BNCT treated group due to metabolic inactivation of ablated tumor tisue.


Conclusion: This study revealed that BNCT
treatment can be successfully performed by using our novel 10B carrier 10BDG
in the management of PCa. We suppose that this novel 10B carrier can take
place as a safe and effective agent in routine clinical practice of BNCT.

Keywords

BNCT Prostate cancer Rat model BDG FDG PET

References

  • 1. Barth, R.F., Coderre, J.A., Vincente, M.G.H., Blue, T.E., 2005. Boron neutron capture therapy of cancer: current status and future prospects. Clincal Cancer Research 11, 3987–4002.
  • 2. Corderre, J.A., Chanana, A.D., Joel, D.D., Elowitz, E.H., Micca, P.L., Nawrocky, M.M., Chadha, M., Gebbers, J-O., Shady, M., Peress, N.S., Slatkin, D.N., 1998. Biodis- tribution of boronophenylalanine in patients with glioblastoma multiform: boron concentration correlates with tumor cellularity. Radiation Research 149, 163–170.
  • 3. Coderre JA, Morris GM. The radiation biology of boron neutron capture therapy. Radiation research. 1999; 151(1):1–18.
  • 4. Uusi-Simola J, Savolainen S, Kangasmaki A, Heikkinen S, Perkio J, Ramadan UA, et al. Study of the relative dose-response of BANG-3((R)) polymer gel dosimeters in epithermal neutron irradiation. Physics in Medicine and Biology. 2003;48(17):2895-906.
  • 5. van Rij CM, Wilhelm AJ, Sauerwein WAG, van Loenen AC. Boron neutron capture therapy for glioblastoma multiforme. Pharmacy World & Science. 2005;27(2):92-5.
  • 6. Hopewell JW, Gorlia T, Pellettieri L, Giusti V, H-Stenstam B, Skold K. Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: An assessment of clinical potential. Applied Radiation and Isotopes. 2011;69(12):1737-40.
  • 7. Barth, R.F.; Soloway, A.H.; Brugger, R.M. Boron neutron capture therapy of brain tumors: past history, current status, and future potential. Cancer Investig. 1996, 14, 534–550.
  • 8. Lu, D.R.; Mehta, S.C.; Chen, W. Selective boron drug delivery to brain tumors for boron neutron capture therapy. Adv. Drug Deliv. Rev. 1997, 26, 231–247.
  • 9. Soloway, A.H.; Tjarks, W.; Barnum, B.A.; Rong, F.; Barth, R.F.; Codognic, I.M.; Wilson, J.G. The chemistry of neutron capture therapy. Chem. Rev. 1998, 98, 1515–1562.
  • 10. Barth, R.E. A critical assessment of neutron capture therapy; an overview. J. Neuroncol. 2003, 62, 1-5.

Year 2016, Volume: 3 Issue: 12, 350 - 358, 29.12.2016

Zafer Akan Hulya Ozdemir Mehmet Bilgehan Yuksel Gokhan Oto Hatice Sinav Uslu Mehmet Turkmen

https://doi.org/10.17546/msd.270421

Abstract

References

  • 1. Barth, R.F., Coderre, J.A., Vincente, M.G.H., Blue, T.E., 2005. Boron neutron capture therapy of cancer: current status and future prospects. Clincal Cancer Research 11, 3987–4002.
  • 2. Corderre, J.A., Chanana, A.D., Joel, D.D., Elowitz, E.H., Micca, P.L., Nawrocky, M.M., Chadha, M., Gebbers, J-O., Shady, M., Peress, N.S., Slatkin, D.N., 1998. Biodis- tribution of boronophenylalanine in patients with glioblastoma multiform: boron concentration correlates with tumor cellularity. Radiation Research 149, 163–170.
  • 3. Coderre JA, Morris GM. The radiation biology of boron neutron capture therapy. Radiation research. 1999; 151(1):1–18.
  • 4. Uusi-Simola J, Savolainen S, Kangasmaki A, Heikkinen S, Perkio J, Ramadan UA, et al. Study of the relative dose-response of BANG-3((R)) polymer gel dosimeters in epithermal neutron irradiation. Physics in Medicine and Biology. 2003;48(17):2895-906.
  • 5. van Rij CM, Wilhelm AJ, Sauerwein WAG, van Loenen AC. Boron neutron capture therapy for glioblastoma multiforme. Pharmacy World & Science. 2005;27(2):92-5.
  • 6. Hopewell JW, Gorlia T, Pellettieri L, Giusti V, H-Stenstam B, Skold K. Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: An assessment of clinical potential. Applied Radiation and Isotopes. 2011;69(12):1737-40.
  • 7. Barth, R.F.; Soloway, A.H.; Brugger, R.M. Boron neutron capture therapy of brain tumors: past history, current status, and future potential. Cancer Investig. 1996, 14, 534–550.
  • 8. Lu, D.R.; Mehta, S.C.; Chen, W. Selective boron drug delivery to brain tumors for boron neutron capture therapy. Adv. Drug Deliv. Rev. 1997, 26, 231–247.
  • 9. Soloway, A.H.; Tjarks, W.; Barnum, B.A.; Rong, F.; Barth, R.F.; Codognic, I.M.; Wilson, J.G. The chemistry of neutron capture therapy. Chem. Rev. 1998, 98, 1515–1562.
  • 10. Barth, R.E. A critical assessment of neutron capture therapy; an overview. J. Neuroncol. 2003, 62, 1-5.
There are 10 citations in total.

Details

Subjects Health Care Administration
Journal Section Research Article
Authors

Zafer Akan

Hulya Ozdemir This is me

Mehmet Bilgehan Yuksel

Gokhan Oto This is me

Hatice Sinav Uslu

Mehmet Turkmen This is me

Publication Date December 29, 2016
Published in Issue Year 2016 Volume: 3 Issue: 12

Cite

APA Akan, Z., Ozdemir, H., Yuksel, M. B., Oto, G., et al. (2016). The treatment of metastatic prostate carcinoma with BNCT in the ITU TRIGA MARKII reactor on rat model. Medical Science and Discovery, 3(12), 350-358. https://doi.org/10.17546/msd.270421
AMA Akan Z, Ozdemir H, Yuksel MB, Oto G, Uslu HS, Turkmen M. The treatment of metastatic prostate carcinoma with BNCT in the ITU TRIGA MARKII reactor on rat model. Med Sci Discov. December 2016;3(12):350-358. doi:10.17546/msd.270421
Chicago Akan, Zafer, Hulya Ozdemir, Mehmet Bilgehan Yuksel, Gokhan Oto, Hatice Sinav Uslu, and Mehmet Turkmen. “The Treatment of Metastatic Prostate Carcinoma With BNCT in the ITU TRIGA MARKII Reactor on Rat Model”. Medical Science and Discovery 3, no. 12 (December 2016): 350-58. https://doi.org/10.17546/msd.270421.
EndNote Akan Z, Ozdemir H, Yuksel MB, Oto G, Uslu HS, Turkmen M (December 1, 2016) The treatment of metastatic prostate carcinoma with BNCT in the ITU TRIGA MARKII reactor on rat model. Medical Science and Discovery 3 12 350–358.
IEEE Z. Akan, H. Ozdemir, M. B. Yuksel, G. Oto, H. S. Uslu, and M. Turkmen, “The treatment of metastatic prostate carcinoma with BNCT in the ITU TRIGA MARKII reactor on rat model”, Med Sci Discov, vol. 3, no. 12, pp. 350–358, 2016, doi: 10.17546/msd.270421.
ISNAD Akan, Zafer et al. “The Treatment of Metastatic Prostate Carcinoma With BNCT in the ITU TRIGA MARKII Reactor on Rat Model”. Medical Science and Discovery 3/12 (December 2016), 350-358. https://doi.org/10.17546/msd.270421.
JAMA Akan Z, Ozdemir H, Yuksel MB, Oto G, Uslu HS, Turkmen M. The treatment of metastatic prostate carcinoma with BNCT in the ITU TRIGA MARKII reactor on rat model. Med Sci Discov. 2016;3:350–358.
MLA Akan, Zafer et al. “The Treatment of Metastatic Prostate Carcinoma With BNCT in the ITU TRIGA MARKII Reactor on Rat Model”. Medical Science and Discovery, vol. 3, no. 12, 2016, pp. 350-8, doi:10.17546/msd.270421.
Vancouver Akan Z, Ozdemir H, Yuksel MB, Oto G, Uslu HS, Turkmen M. The treatment of metastatic prostate carcinoma with BNCT in the ITU TRIGA MARKII reactor on rat model. Med Sci Discov. 2016;3(12):350-8.
 Download Cover Image